Design, Synthesis, SAR Discussion, in Vitro and in Vivo Evaluation of Novel Selective EGFR Modulator to Inhibit L858R/T790M Double Mutants

Haoyang Zhang,Wenkui Wu,Chao Feng,Zhaogang Liu,Enhe Bai,Xueyuan Wang,Meng Lei,Hao Cheng,Huayun Feng,Jingmiao Shi,Jia Wang,Zhao Zhang,Tao Jin,Shanshan Chen,Shihe Hu,Yongqiang Zhu
DOI: https://doi.org/10.1016/j.ejmech.2017.04.036
IF: 7.088
2017-01-01
European Journal of Medicinal Chemistry
Abstract:Based upon the modeling binding mode of marketed AZD9291 with T790M, a series of 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline derivatives were designed and synthesized with the purpose to overcome the drug resistance resulted from T790M/L858R double mutations. The most potent compound 8 showed excellent enzyme inhibitory activities and selectivity with sub nanomolar IC50 values for both the single L858R and double T790M/L858R mutant EGFRs, and was more than 8-fold selective for wild type EGFR. Compound 8 exhibited good microsomes stabilities and pharmacokinetic properties and lower binding affinity to hERG ion channel than AZD9291 and displayed strong antiproliferative activity against the H1975 non-small cell lung cancer (NSCLC) cells bearing T790M/L858R and in vivo anticancer efficacy in a human NSCLC (H1975) xenograft mouse model.
What problem does this paper attempt to address?